Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells

Biochemical and Biophysical Research Communications

Volumn 298, Issue 4, 2002, Pages 603-612

  Sliva, Daniel ^a,b   Labarrere, Carlos ^a   Slivova, Veronika ^a   Sedlak, Miroslav ^c   Lloyd, Frank P ^a   Ho, Nancy W Y ^c  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

AP 1; Cancer; Cell migration; Ganoderma lucidum; MDA MB 231; NF B; PC 3; uPA; uPAR

Indexed keywords

GANODERMA LUCIDUM EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; UROKINASE; UROKINASE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DRUG MECHANISM; FRUITING BODY; FUNGUS SPORE; GANODERMA LUCIDUM; HUMAN; HUMAN CELL; POWDER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SECRETION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL MOVEMENT; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NF-KAPPA B; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; REISHI; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

FUNGI; GANODERMA; GANODERMA LUCIDUM;

EID: 0036429277     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)02496-8     Document Type: Article

References (54)

1. T.K. Yun, Update from Asia. Asian studies on cancer chemo-prevention, Ann. NY Acad. Sci. 889 (1999) 157-192.
2. S.S. Kim, Y.S. Kim, in: Korean Mushrooms, Yupoong, Seoul, 1999, pp. 298-299.
3. S.P. Wasser, A.L. Weis, Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: A modern perspective, Crit. Rev. Immunol. 19 (1999) 65-96.
4. Y. Mizushina, L. Hanashima, T. Yamaguchi, M. Takemura, F. Sugawara, M. Saneyoshi, A. Matsukage, S. Yoshida, K. Sakaguchi, A mushroom fruiting body-inducing substance inhibits activities of replicative DNA polymerases, Biochem. Biophys. Res. Commun. 249 (1998) 17-22.
5. B.S. Min, J.J. Gao, N. Nakamura, M. Hattori, Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against meth-A and LLC tumor cells, Chem. Pharm. Bull. 48 (2000) 1026-1033.
6. T. Miyazaki, M. Nishijima, Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganoderma lucidum, Chem. Pharmacol. Bull. 29 (1981) 3611-3616.
7. Y. Sone, R. Okuda, N. Wada, E. Kishida, A. Misaki, Structures and antitumor activities of the polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma Lucidum, Agric. Biol. Chem. 49 (1985) 2641-2653.
8. S.Y. Wang, M.L. Hsu, H.C. Hsu, S.S. Lee, M.S. Shiao, C.K. Ho, The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes, Int. J. Cancer 70 (1997) 699-705.
9. J.T. Price, M.T. Bonovich, E.C. Kohn, The biochemistry of cancer dissemination, Crit. Rev. Biochem. Mol. Biol. 32 (1997) 175-253.
10. P.A. Andreasen, L. Kjøller, L. Christensen, M.J. Duffy, The urokinase-type plasminogen activator system in cancer metastasis: A review, Int. J. Cancer 72 (1997) 1-22.
11. F. Blasi, uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways? Immunol. Today 18 (1997) 415-417.
12. Y. Sato, D. Rifkin, Autocrine activities of basic fibroblast growth factor: Regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis, J. Cell Biol. 107 (1988) 1199-1205.
13. Y. Sato, D. Rifkin, Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture, J. Cell Biol. 109 (1990) 309-315.
14. G. Fibbi, M. Ziche, L. Morbidelli, L. Magnelli, M. Del Rosso, Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells, Exp. Cell Res. 179 (1988) 385-395.
15. L.E. Odekon, Y. Sato, D. Rifkin, Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity, J. Cell. Physiol. 150 (1992) 258-263.
16. N. Busso, S.K. Masur, D. Lazega, S. Waxman, L. Ossowski, Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells, J. Cell Biol. 126 (1994) 259-270.
17. M. Resnati, M. Guttinger, S. Valcamonica, N. Sidenius, F. Blasi, F. Fazioli, Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect, EMBO J. 15 (1996) 1572-1582.
18. L. Ossowski, E. Reich, Antibodies to plasminogen activator inhibit human tumor metastasis, Cell 35 (1983) 611-619.
19. Y.H. Kook, J. Adamski, A. Zelent, L. Ossowski, The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy, EMBO J. 13 (1994) 3983-3991.
20. A.P. Mazar, The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer, Anticancer Drugs 12 (2001) 387-400.
21. A. Jemal, A. Thomas, T. Murray, M. Thun, Cancer statistics, CA Cancer J. Clin. 52 (2002) 23-47.
22. H. Nakshatri, P. Bhat-Nakshatri, D.A. Martin, R.J. Goulet Jr., G.W. Sledge Jr., Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth, Mol. Cell. Biol. 17 (1997) 3629-3639.
23. M.E. Taplin, G.J. Bubley, T.D. Shuster, M.E. Frantz, A.E. Spooner, G.K. Ogata, H.N. Keer, S.P. Balk, Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer, N. Engl. J. Med. 332 (1995) 1393-1398.
24. C. Nerlov, P. Rorth, F. Blasi, M. Johnsen, Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity, Oncogene 6 (1991) 1583-1592.
25. E. Lengyel, R. Gum, E. Stepp, J. Juarez, H. Wang, D. Boyd, Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line, J. Cell. Biochem. 61 (1996) 430-443.
26. Y. Wang, The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis, Med. Res. Rev. 21 (2001) 146-170.
27. M.A. Sovak, R.E. Bellas, D.W. Kim, G.J. Zanieski, A.E. Rogers, A.M. Traish, G.E. Sonenshein, Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer, J. Clin. Invest. 100 (1997) 2952-2960.
28. P.J. Daschner, H.P. Ciolino, C.A. Plouzek, G.C. Yeh, Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells, Breast Cancer Res. Treat. 53 (1999) 229-240.
29. S.T. Palayoor, M.Y. Youmell, S.K. Calderwood, C.N. Coleman, B.D. Price, Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen, Oncogene 18 (1999) 7389-7394.
30. B. Stein, A.S. Baldwin Jr., D.W. Ballard, W.C. Greene, P. Angel, P. Herrlich, Cross-coupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function, EMBO J. 12 (1993) 3879-3891.
31. D. Sliva, M.T. Rizzo, D. English, Phosphatidylinositol 3-kinase and NF-κB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator, J. Biol. Chem. 277 (2002) 3150-3157.
32. D. Sliva, D. English, D. Lyons, F.P. Lloyd Jr., Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-κB, Biochem. Biophys. Res. Commun. 290 (2002) 552-557.
33. D. Sliva, R. Mason, H. Xiao, D. English, Enhancement of the migration of metastatic human breast cancer cells by phosphatidic acid, Biochem. Biophys. Res. Commun. 268 (2000) 471-479.
34. H.J. Phillips, J.E. Terryberry, Counting actively metabolizing tissue cultured cells, Exp. Cell Res. 13 (1957) 341-347.
35. D. Sliva, T.J.J. Wood, C. Schindler, P.E. Lobie, G. Norstedt, Growth hormone specifically regulates serine protease inhibitor gene transcription via γ-activated sequence-like DNA elements, J. Biol. Chem. 269 (1994) 26208-26214.
36. D. Sliva, Y.X. Zhu, S. Tsai, J. Kamine, Y.C. Yang, Tip60 interacts with human interleukin-9 receptor α-chain, Biochem. Biophys. Res. Commun. 263 (1999) 149-155.
37. A. Agresti, Categorical Data Analysis, Wiley, New York, 1990.
38. A.S. Baldwin Jr., The NF-κB and IκB proteins: New discoveries and insights, Annu. Rev. Immunol. 14 (1996) 649-683.
39. N. Sizemore, S. Leung, G.R. Stark, Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-κB p65/RelA subunit, Mol. Cell. Biol. 19 (1999) 4798-4805.
40. J.M. Kozlowski, H.N. Keer, F.D. Gaylis, C. Lee, Increased urokinase-plasminogen activator (u-PA) expression correlates with aggressive phenotype in human prostate cancer cells, in: P. Glas-Grenwalt (Ed.), Fibrinolysis in Disease, CRC Press, Boca Raton, 1995, pp. 41-50.
41. W.H. Lin, C.H. Hung, C.I. Hsu, J.Y. Lin, Dimerization of the N-terminal amphipathic α-helix domain of the fungal immunomodulatory protein from Ganoderma tsugae (Fip-gts) defined by a yeast two-hybrid system and site-directed mutagenesis, J. Biol. Chem. 272 (1997) 20044-20048.
42. S. Lee, S. Park, J.W. Oh, C. Yang, Natural inhibitors for protein prenyltransferase, Planta Med. 64 (1998) 303-308.
43. W.M.W. Cheung, W.S. Hui, P.W.K. Chu, S.W. Chiu, N.Y. Ip, Ganoderma extract activates MAP kinases and induces the neuronal differentiation of rat pheochromocytoma PC12 cells, FEBS Lett. 486 (2000) 291-296.
44. J.H. Ludes-Meyers, Y. Liu, D. Munoz-Medellin, S.G. Hilsenbeck, P.H. Brown, AP-1 blockade inhibits the growth of normal and malignant breast cells, Oncogene 20 (2001) 2771-2780.
45. C.Y. Wang, J.C. Cusack Jr., R. Liu, A.S. Baldwin Jr., Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB, Nature Med. 5 (1999) 412-417.
46. J.C. Cusack Jr., R. Liu, M. Houston, K. Abendroth, P.J. Elliott, J. Adams, A.S. Baldwin Jr., Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition, Cancer Res. 61 (2001) 3535-3540.
47. R. Chang, E-ective dose of Ganoderma in humans, in: Proceedings of the Contributed Symposium 59A, B 5th International Mycological Congress, Vancouver, 1994, pp. 117-121.
48. M. Karin, The beginning of the end: IκB kinase (IKK) and NF-κB activation, J. Biol. Chem. 274 (1999) 27339-27342.
49. L.V. Madrid, C.Y. Wang, D.C. Cuttridge, A.J.G. Schottelius, A.S. Baldwin Jr., M.W. Mayo, Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB, Mol. Cell. Biol. 20 (2000) 1626-1638.
50. N. Sizemore, N. Lerner, N. Dombrowski, H. Sakurai, G.R. Stark, Distinct roles of the IκB kinase α and β subunits in liberating nuclear factor κB (NF-κB) from IκB and in phosphorylating the p65 subunit of NF-κB, J. Biol. Chem . 277 (2002) 3863-3869.
51. D.M. Eisenberg, R.B. Davis, S.L. Ettner, S. Appel, S. Wilkey, M. VanRompay, R.C. Kessler, Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey, JAMA 280 (1998) 1569-1575.
52. A. de la Taille, O.R. Hayek, M. Burchardt, T. Burchardt, A.E. Katz, Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: Two case reports, J. Alter. Complement. Med. 6 (2000) 449-451.
53. R.S. Di Paola, H. Zhang, G.H. Lambert, R. Meeker, E. Licitra, M.M. Rafi, B.T. Zhu, H. Spaulding, S. Goodin, M.B. Toledano, W.N. Hait, M.A. Gallo, Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer, N. Engl. J. Med. 339 (1998) 785-787.
54. A. de la Taille, O.R. Hayek, R. Buttyan, B. Bagiella, M. Burchardt, A.E. Katz, Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: A preliminary investigation on human cell lines and patients, Br. J. Urol. 84 (1999) 845-850.